Evaluation of recombinant human bone morphogenetic protein-2 on the repair of alveolar ridge defects in baboons

Dario A O Miranda, Neil M. Blumenthal, Rachel G. Sorensen, John M. Wozney, Ulf M E Wikesjö

Research output: Contribution to journalArticle

46 Citations (Scopus)

Abstract

Background: The objective of this study was to evaluate alveolar ridge augmentation following surgical implantation of recombinant human bone morphogenetic protein-2 (rhBMP-2) using two novel space-providing carrier technologies in the baboon (Papio anubis) model. Methods: Standardized alveolar ridge defects (∼15 × 8 × 5 mm) were surgically produced in maxillary and mandibular edentulous areas in four baboons. The defect sites were implanted with rhBMP-2 (0.4 mg/mL) in a tricalcium phosphate/hydroxyapatite/absorbable collagen sponge composite (TCP/HA/ACS) or calcium phosphate cement (α-BSM). Control treatments were TCP/HA/ACS and α-BSM without rhBMP-2 and sham surgery. Stainless steel pins were placed at the mid-apical and coronal level of the defect sites to provide landmarks for clinical measurements pre- and post-implantation. Impressions were obtained pre- and post-implantation to determine changes in alveolar ridge volume. Radiographic registrations were obtained pre- and post-implantation. Block sections of the defect sites were harvested at week 16 post-implantation and processed for histometric analysis including new bone area and bone density. Statistical comparisons between treatments were made using a mixed effect generalized linear model using least squares estimation. Results: The carrier systems without rhBMP-2 provided a modest ridge augmentation. The addition of rhBMP-2 resulted in an almost 2-fold increase in alveolar ridge width, including a greater percentage of trabecular bone and a higher bone density compared to controls (P≤0.05) without significant differences between the two rhBMP-2 protocols. Conclusions: TCP/HA/ACS and αBSM appear to be suitable carrier technologies for rhBMP-2. Alveolar augmentation procedures using either technology combined with rhBMP-2, rather than stand-alone therapies, may provide clinically relevant augmentation of alveolar ridge defects for placement of endosseous dental implants.

Original languageEnglish (US)
Pages (from-to)210-220
Number of pages11
JournalJournal of Periodontology
Volume76
Issue number2
DOIs
StatePublished - Feb 1 2005

Fingerprint

Alveolar Process
Papio
Porifera
Alveolar Ridge Augmentation
Durapatite
Collagen
Technology
Bone Density
Papio anubis
Dental Implants
recombinant human bone morphogenetic protein-2
Stainless Steel
Least-Squares Analysis
Linear Models
Bone and Bones

Keywords

  • Alveolar ridge augmentation
  • Animal studies
  • Calcium phosphates/therapeutic use
  • Clinical protocols
  • Collagen/therapeutic use
  • Proteins, bone morphogenetic

ASJC Scopus subject areas

  • Periodontics

Cite this

Miranda, D. A. O., Blumenthal, N. M., Sorensen, R. G., Wozney, J. M., & Wikesjö, U. M. E. (2005). Evaluation of recombinant human bone morphogenetic protein-2 on the repair of alveolar ridge defects in baboons. Journal of Periodontology, 76(2), 210-220. https://doi.org/10.1902/jop.2005.76.2.210

Evaluation of recombinant human bone morphogenetic protein-2 on the repair of alveolar ridge defects in baboons. / Miranda, Dario A O; Blumenthal, Neil M.; Sorensen, Rachel G.; Wozney, John M.; Wikesjö, Ulf M E.

In: Journal of Periodontology, Vol. 76, No. 2, 01.02.2005, p. 210-220.

Research output: Contribution to journalArticle

Miranda, Dario A O ; Blumenthal, Neil M. ; Sorensen, Rachel G. ; Wozney, John M. ; Wikesjö, Ulf M E. / Evaluation of recombinant human bone morphogenetic protein-2 on the repair of alveolar ridge defects in baboons. In: Journal of Periodontology. 2005 ; Vol. 76, No. 2. pp. 210-220.
@article{dab31cd126dd42dc8c89dd1edde1dca1,
title = "Evaluation of recombinant human bone morphogenetic protein-2 on the repair of alveolar ridge defects in baboons",
abstract = "Background: The objective of this study was to evaluate alveolar ridge augmentation following surgical implantation of recombinant human bone morphogenetic protein-2 (rhBMP-2) using two novel space-providing carrier technologies in the baboon (Papio anubis) model. Methods: Standardized alveolar ridge defects (∼15 × 8 × 5 mm) were surgically produced in maxillary and mandibular edentulous areas in four baboons. The defect sites were implanted with rhBMP-2 (0.4 mg/mL) in a tricalcium phosphate/hydroxyapatite/absorbable collagen sponge composite (TCP/HA/ACS) or calcium phosphate cement (α-BSM). Control treatments were TCP/HA/ACS and α-BSM without rhBMP-2 and sham surgery. Stainless steel pins were placed at the mid-apical and coronal level of the defect sites to provide landmarks for clinical measurements pre- and post-implantation. Impressions were obtained pre- and post-implantation to determine changes in alveolar ridge volume. Radiographic registrations were obtained pre- and post-implantation. Block sections of the defect sites were harvested at week 16 post-implantation and processed for histometric analysis including new bone area and bone density. Statistical comparisons between treatments were made using a mixed effect generalized linear model using least squares estimation. Results: The carrier systems without rhBMP-2 provided a modest ridge augmentation. The addition of rhBMP-2 resulted in an almost 2-fold increase in alveolar ridge width, including a greater percentage of trabecular bone and a higher bone density compared to controls (P≤0.05) without significant differences between the two rhBMP-2 protocols. Conclusions: TCP/HA/ACS and αBSM appear to be suitable carrier technologies for rhBMP-2. Alveolar augmentation procedures using either technology combined with rhBMP-2, rather than stand-alone therapies, may provide clinically relevant augmentation of alveolar ridge defects for placement of endosseous dental implants.",
keywords = "Alveolar ridge augmentation, Animal studies, Calcium phosphates/therapeutic use, Clinical protocols, Collagen/therapeutic use, Proteins, bone morphogenetic",
author = "Miranda, {Dario A O} and Blumenthal, {Neil M.} and Sorensen, {Rachel G.} and Wozney, {John M.} and Wikesj{\"o}, {Ulf M E}",
year = "2005",
month = "2",
day = "1",
doi = "10.1902/jop.2005.76.2.210",
language = "English (US)",
volume = "76",
pages = "210--220",
journal = "Journal of Periodontology",
issn = "0022-3492",
publisher = "American Academy of Periodontology",
number = "2",

}

TY - JOUR

T1 - Evaluation of recombinant human bone morphogenetic protein-2 on the repair of alveolar ridge defects in baboons

AU - Miranda, Dario A O

AU - Blumenthal, Neil M.

AU - Sorensen, Rachel G.

AU - Wozney, John M.

AU - Wikesjö, Ulf M E

PY - 2005/2/1

Y1 - 2005/2/1

N2 - Background: The objective of this study was to evaluate alveolar ridge augmentation following surgical implantation of recombinant human bone morphogenetic protein-2 (rhBMP-2) using two novel space-providing carrier technologies in the baboon (Papio anubis) model. Methods: Standardized alveolar ridge defects (∼15 × 8 × 5 mm) were surgically produced in maxillary and mandibular edentulous areas in four baboons. The defect sites were implanted with rhBMP-2 (0.4 mg/mL) in a tricalcium phosphate/hydroxyapatite/absorbable collagen sponge composite (TCP/HA/ACS) or calcium phosphate cement (α-BSM). Control treatments were TCP/HA/ACS and α-BSM without rhBMP-2 and sham surgery. Stainless steel pins were placed at the mid-apical and coronal level of the defect sites to provide landmarks for clinical measurements pre- and post-implantation. Impressions were obtained pre- and post-implantation to determine changes in alveolar ridge volume. Radiographic registrations were obtained pre- and post-implantation. Block sections of the defect sites were harvested at week 16 post-implantation and processed for histometric analysis including new bone area and bone density. Statistical comparisons between treatments were made using a mixed effect generalized linear model using least squares estimation. Results: The carrier systems without rhBMP-2 provided a modest ridge augmentation. The addition of rhBMP-2 resulted in an almost 2-fold increase in alveolar ridge width, including a greater percentage of trabecular bone and a higher bone density compared to controls (P≤0.05) without significant differences between the two rhBMP-2 protocols. Conclusions: TCP/HA/ACS and αBSM appear to be suitable carrier technologies for rhBMP-2. Alveolar augmentation procedures using either technology combined with rhBMP-2, rather than stand-alone therapies, may provide clinically relevant augmentation of alveolar ridge defects for placement of endosseous dental implants.

AB - Background: The objective of this study was to evaluate alveolar ridge augmentation following surgical implantation of recombinant human bone morphogenetic protein-2 (rhBMP-2) using two novel space-providing carrier technologies in the baboon (Papio anubis) model. Methods: Standardized alveolar ridge defects (∼15 × 8 × 5 mm) were surgically produced in maxillary and mandibular edentulous areas in four baboons. The defect sites were implanted with rhBMP-2 (0.4 mg/mL) in a tricalcium phosphate/hydroxyapatite/absorbable collagen sponge composite (TCP/HA/ACS) or calcium phosphate cement (α-BSM). Control treatments were TCP/HA/ACS and α-BSM without rhBMP-2 and sham surgery. Stainless steel pins were placed at the mid-apical and coronal level of the defect sites to provide landmarks for clinical measurements pre- and post-implantation. Impressions were obtained pre- and post-implantation to determine changes in alveolar ridge volume. Radiographic registrations were obtained pre- and post-implantation. Block sections of the defect sites were harvested at week 16 post-implantation and processed for histometric analysis including new bone area and bone density. Statistical comparisons between treatments were made using a mixed effect generalized linear model using least squares estimation. Results: The carrier systems without rhBMP-2 provided a modest ridge augmentation. The addition of rhBMP-2 resulted in an almost 2-fold increase in alveolar ridge width, including a greater percentage of trabecular bone and a higher bone density compared to controls (P≤0.05) without significant differences between the two rhBMP-2 protocols. Conclusions: TCP/HA/ACS and αBSM appear to be suitable carrier technologies for rhBMP-2. Alveolar augmentation procedures using either technology combined with rhBMP-2, rather than stand-alone therapies, may provide clinically relevant augmentation of alveolar ridge defects for placement of endosseous dental implants.

KW - Alveolar ridge augmentation

KW - Animal studies

KW - Calcium phosphates/therapeutic use

KW - Clinical protocols

KW - Collagen/therapeutic use

KW - Proteins, bone morphogenetic

UR - http://www.scopus.com/inward/record.url?scp=17444373539&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=17444373539&partnerID=8YFLogxK

U2 - 10.1902/jop.2005.76.2.210

DO - 10.1902/jop.2005.76.2.210

M3 - Article

VL - 76

SP - 210

EP - 220

JO - Journal of Periodontology

JF - Journal of Periodontology

SN - 0022-3492

IS - 2

ER -